Monday, October 29, 2018
Guardant Health initiated at Cowen
Guardant Health initiated with an Outperform at Cowen. Cowen analyst Doug Schenkel initiated Guardant Health with an Outperform rating. The analyst said the company is strongly positioned as the market leader in liquid biopsy comprehensive genetic profiling of cancer patients and as a trusted partner for a growing number of major biopharma partners. Schenkel has a $40 price target on Guardant Health shares.
https://thefly.com/landingPageNews.php?id=2812537
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.